118 results on '"Galli, L."'
Search Results
2. 1469P Efficacy and safety of pembrolizumab/axitinib combination in metastatic renal cell carcinoma (mRCC): A multicentric prospective analysis (ProPAXI study)
3. 1843P Safety of immunotherapy in cancer patients with comorbidities: Results of the phase IV Italian immuno-special trial
4. B21 - 223Ra-chloride therapy: the first multidisciplinary and multicenter Italian study
5. B3 - Impact of metabolic syndrome on clinical outcome of castration resistant prostate cancer (CRPC) patients treated with abiraterone and enzalutamide
6. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
7. 695P Drug-drug interactions between pazopanib and proton pump inhibitors may significantly affect clinical outcome of patients affected by metastatic renal cell carcinoma
8. 696P Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)
9. 750P Safety and efficacy of platinum desensitization treatment in patients with ovarian cancer and platinum hypersensitivity
10. 1895P Time to treatment failure (TTF) and treatment beyond progression (TBP) in pretreated metastatic renal cell carcinoma (mRCC) patients (pts) receiving nivolumab: A survival outcome and a therapeutic strategy of clinical benefit (meet-uro 15)
11. 2097P Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
12. 290P Metabolomic profiling and response to neoadjuvant therapy (NAT) in early breast cancer (EBC)
13. 1711P SARS-CoV-2 infection in prostate cancer patients: Data from a high-incidence area in Italy
14. 768P Prognostic score combining systemic inflammation index (SII) and PD-L1 +/- LDH in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis in the Italian population of the SAUL study
15. EGFR AND HER-2/NEU EVALUATION IN PATIENTS WITH RECURRENT NSCLC TREATED WITH ZD1839 (IRESSA) ON A COMPASSIONATE USE PROTOCOL
16. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide
17. EFFICACY OF 1-MONTH LANREOTIDE IN PATIENTS WITH NEUROENDOCRINE TUMOURS: PRELIMINARY RESULTS OF A ITALIAN MULTICENTER STUDY
18. GEMCITABINE (GEM) PLUS EPIRUBICIN (EPI) IN PATIENTS (PTS) WITH ADVANCED UROTHELIAL CANCER. PRELIMINARY RESULTS OF A PHASE II STUDY.
19. HIGH-DOSE ONDANSETRON (OND) AND DEXAMETASONE (DEX) TO PREVENT ACUTE AND DELAYED EMESIS IN PATIENTS (PTS) RECEIVING HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HAEMOPOIETIC SUPPORT (AHS).
20. Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
21. Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
22. Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre
23. Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: Independent actors or reciprocal drivers? A translational study by Meet-Uro group
24. Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study
25. 223Ra-chloride therapy: the first multidisciplinary and multicenter Italian study
26. Impact of metabolic syndrome on clinical outcome of castration resistant prostate cancer (CRPC) patients treated with abiraterone and enzalutamide
27. Metabolic syndrome and inflammation in castration resistant prostate cancer (CRPC) patients (pts) treated with abiraterone (abi) and enzalutamide (enza)
28. Negative prognostic factors and resulting clinical outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) included in the Italian nivolumab expanded access program (EAP)
29. Efficacy and safety data in elderly patients (pts) with metastatic renal cell carcinoma (mRCC) included in the nivolumab expanded access program (EAP) in Italy
30. Treatment beyond progression in patients with advanced RCC participating in the expanded access programme (EAP)
31. 1759P - Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre
32. 927P - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
33. 861P - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
34. Antiemetic prophylaxis (AP) in our clinical practice: are we doing it right?
35. The prostate cancer registry: Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC)
36. Outcome of patients with multiple glandular metastases from renal cell carcinoma treated with targeted agents
37. Enhancer of zest homolog 2 (EZH2) expression in well and moderately differentiated pancreatic neuroendocrine tumor (pNET)
38. Progressing G1-G2 neuroendocrine tumors (WD NET) in treatment with capecitabine (Cp) plus somatostatin analog (SSA): a single center experience
39. AR-V7 detection in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer
40. First Italian Multicentre Experience in using Ra-223 in patients with metastatic castration resistant prostate cancer (mCRPC)
41. The detection of AR-V7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients
42. Multicenter retrospective study on new biomarkers predictive of response to sunitinib in metastatic renal cell carcinoma
43. Brain and pancreatic metastases: a clinico-pathological comparison of various facets of the tumor heterogeneity in renal cell carcinoma_The BRAVE project
44. Effectiveness of Axitinib second-line therapy for metastatic renal cell carcinoma: preliminary results from real-word “SAX” observational study
45. G1-G2 Neuroendocrine Tumors (WD NET) in treatment with Capecitabine (Cp) plus somatostatin analog (SSA)
46. Enhancer of zeste homolog 2 (EZH2) expression in G1 -G2 Pancreatic Neuroendocrine Tumor (pNET)
47. Correction to: Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
48. 891P - Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study
49. 88P - Role of AR-V7 and AR-FL in resistance to hormonal therapy in mCRPC: Independent actors or reciprocal drivers? A translational study by Meet-Uro group
50. Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.